BAIT
FLT3
CD135, FLK-2, FLK2, STK1, RP11-153M24.3
fms-related tyrosine kinase 3
GO Process (21)
GO Function (5)
GO Component (1)
Gene Ontology Biological Process
- B cell differentiation [ISS]
- cellular response to cytokine stimulus [ISS, TAS]
- common myeloid progenitor cell proliferation [ISS]
- cytokine-mediated signaling pathway [ISS]
- dendritic cell differentiation [ISS]
- hemopoiesis [IDA]
- leukocyte homeostasis [ISS]
- lymphocyte proliferation [ISS]
- myeloid progenitor cell differentiation [ISS]
- peptidyl-tyrosine phosphorylation [TAS]
- positive regulation of MAP kinase activity [TAS]
- positive regulation of MAPK cascade [TAS]
- positive regulation of cell proliferation [TAS]
- positive regulation of phosphatidylinositol 3-kinase activity [TAS]
- positive regulation of phosphatidylinositol 3-kinase signaling [TAS]
- positive regulation of tyrosine phosphorylation of STAT protein [TAS]
- pro-B cell differentiation [ISS]
- protein autophosphorylation [TAS]
- regulation of apoptotic process [TAS]
- transmembrane receptor protein tyrosine kinase signaling pathway [TAS]
- vascular endothelial growth factor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
UBC
HMG20
ubiquitin C
GO Process (75)
GO Function (3)
GO Component (6)
Gene Ontology Biological Process
- DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [TAS]
- DNA repair [TAS]
- Fc-epsilon receptor signaling pathway [TAS]
- G1/S transition of mitotic cell cycle [TAS]
- G2/M transition of mitotic cell cycle [TAS]
- I-kappaB kinase/NF-kappaB signaling [TAS]
- JNK cascade [TAS]
- MyD88-dependent toll-like receptor signaling pathway [TAS]
- MyD88-independent toll-like receptor signaling pathway [TAS]
- Notch receptor processing [TAS]
- Notch signaling pathway [TAS]
- RNA metabolic process [TAS]
- T cell receptor signaling pathway [TAS]
- TRIF-dependent toll-like receptor signaling pathway [TAS]
- activation of MAPK activity [TAS]
- anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process [TAS]
- antigen processing and presentation of exogenous peptide antigen via MHC class I [TAS]
- antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [TAS]
- antigen processing and presentation of peptide antigen via MHC class I [TAS]
- apoptotic process [TAS]
- apoptotic signaling pathway [TAS]
- carbohydrate metabolic process [TAS]
- cellular response to hypoxia [TAS]
- cytokine-mediated signaling pathway [TAS]
- endosomal transport [TAS]
- epidermal growth factor receptor signaling pathway [TAS]
- fibroblast growth factor receptor signaling pathway [TAS]
- gene expression [TAS]
- glucose metabolic process [TAS]
- glycogen biosynthetic process [TAS]
- innate immune response [TAS]
- intracellular transport of virus [TAS]
- ion transmembrane transport [TAS]
- mRNA metabolic process [TAS]
- membrane organization [TAS]
- mitotic cell cycle [TAS]
- negative regulation of apoptotic process [TAS]
- negative regulation of epidermal growth factor receptor signaling pathway [TAS]
- negative regulation of transcription from RNA polymerase II promoter [TAS]
- negative regulation of transforming growth factor beta receptor signaling pathway [TAS]
- negative regulation of type I interferon production [TAS]
- negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [TAS]
- neurotrophin TRK receptor signaling pathway [TAS]
- nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway [TAS]
- nucleotide-binding oligomerization domain containing signaling pathway [TAS]
- positive regulation of I-kappaB kinase/NF-kappaB signaling [TAS]
- positive regulation of NF-kappaB transcription factor activity [TAS]
- positive regulation of apoptotic process [TAS]
- positive regulation of transcription from RNA polymerase II promoter [TAS]
- positive regulation of type I interferon production [TAS]
- positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [TAS]
- protein polyubiquitination [TAS]
- regulation of apoptotic process [TAS]
- regulation of transcription from RNA polymerase II promoter in response to hypoxia [TAS]
- regulation of type I interferon production [TAS]
- regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [TAS]
- small molecule metabolic process [TAS]
- stress-activated MAPK cascade [TAS]
- toll-like receptor 10 signaling pathway [TAS]
- toll-like receptor 2 signaling pathway [TAS]
- toll-like receptor 3 signaling pathway [TAS]
- toll-like receptor 4 signaling pathway [TAS]
- toll-like receptor 5 signaling pathway [TAS]
- toll-like receptor 9 signaling pathway [TAS]
- toll-like receptor TLR1:TLR2 signaling pathway [TAS]
- toll-like receptor TLR6:TLR2 signaling pathway [TAS]
- toll-like receptor signaling pathway [TAS]
- transcription initiation from RNA polymerase II promoter [TAS]
- transcription, DNA-templated [TAS]
- transforming growth factor beta receptor signaling pathway [TAS]
- transmembrane transport [TAS]
- viral life cycle [TAS]
- viral process [TAS]
- viral protein processing [TAS]
- virion assembly [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Affinity Capture-Western
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner identified by Western blot with a specific polyclonal antibody or second epitope tag. This category is also used if an interacting protein is visualized directly by dye stain or radioactivity. Note that this differs from any co-purification experiment involving affinity capture in that the co-purification experiment involves at least one extra purification step to get rid of potential contaminating proteins.
Publication
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.
Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (ATO, As2O3) has been proven effective in treating acute promyelocytic leukemia (APL) and has shown activity in some cases of refractory and relapsed AML and other ... [more]
Oncotarget Aug. 31, 2018; 9(68);32885-32899 [Pubmed: 30250637]
Throughput
- Low Throughput
Curated By
- BioGRID